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Abstract
Telomeres are nucleo-protein structures located at the end of chromosomes
that protect them from degradation. Telomeres length is maintained by the ac‐
tivity of the telomerase complex. These structures are protected by a special‐
ized protein complex named shelterin. In the absence of telomerase activity
and/or protection telomeres are shortened after each round of DNA replica‐
tion. When a critical size is reached, telomeres are recognized as damaged
DNA by the cell p53-dependent DNA-repair system. Persistent activation of
this pathway finally results in cell apoptosis or senescence.
There are a number of rare hereditary diseases caused by the presence of short‐
ened telomeres, collectively named telomeropathies or telomere biology disor‐
ders. In these diseases, cell proliferation is impaired, which results in
premature aging and dysfunction of highly proliferative tissues (bone morrow,
skin and other epithelia). Among them are Dyskeratosis congenita, the Hoyer‐
aal-Hreidarsson, Revesz and Coats plus syndromes, Aplastic anemia, Idiopath‐
ic pulmonary fibrosis and nonalcoholic, noninfectious liver disease. Mutations
present in the genes coding for component of the telomerase and shelterin
complexes and other proteins involved in telomere replication are the cause of
these diseases. Clinical manifestations, causative mutations, diagnosis and pos‐
sible therapeutic approaches to these diseases will be discussed in this chapter.
Keywords: telomere, telomere biology disorders, telomeropathies, pulmonary fibrosis,
bone marrow failure
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1. Introduction
Eukaryotic chromosomes are capped at their ends by specialized nucleo-protein structures,
named telomeres that protect them from degradation. Human telomeres have a specific
nucleotide sequence composed by thousand of repetitions of the TTAGGG hexanucleotide [1].
A protein complex, named shelterin associates to this DNA region to form the telomere-specific
chromatin structure. Telomeres protects the chromosomal ends from degradation and are,
therefore, essential for chromosomal and genome stability [2]. In their absence chromosomal
ends are recognized as damaged DNA by the cell and can be degraded or recombined with
other chromosomal ends resulting in the fusion and reorganization of chromosomes [3]. The
maintenance of telomeres is, therefore, of critical importance for the genetic stability of cells
and organisms.
Replication of telomeric DNA requires the contribution of a specific enzymatic machinery.
DNA polymerases responsible for replication of the rest of the chromosomal DNA cannot
completely synthesize telomeric DNA. DNA polymerases always require a primer molecule
that cover the 5’ end of the DNA and are not able to complete the synthesis of the lagging
strand of lineal DNA molecules, such as chromosomes. This end-replication problem results
in the shortening of each telomere by 50-100 nucleotides at each DNA replication cycle and,
therefore, at each cell division [4]. In most eukaryotic organisms, including humans, telomere
length is maintained by the activity of the telomerase complex that elongates the telomeres by
a replication-independent mechanism [5]. The complex is formed by a protein with reverse-
transcriptase activity (TERT) and one RNA with a region of homology to the telomere DNA
that is used as template for elongation [6]. Telomerase activity is, therefore, required for
unlimited cell proliferation. Telomerase components and, in particular the TERT gene, are
expressed to high relative levels during embryonic development allowing high cell prolifera‐
tion rates. Expression of the TERT gene is, however, repressed in most human adult cells [7].
TERT expression is found only in germinal cells, in stem cells, specially in those of highly
proliferative tissues such as bone marrow and epithelia and in lymphocytes [8]. The rest of the
cells express very low TERT levels and their telomeres get progressively shorter after each cell
division. When telomeres reach a critical size get unprotected and are recognized as damaged
DNA. The ATM and ATR kinases, that regulate cellular responses to DNA damage are
recruited to critically-short telomeres and activate the p53-dependent pathway that results in
cell cycle arrest [3]. Prolonged arrest would finally induce apoptotic cell death or cellular
senescence. Actually, most tissue-specific stem cells do not express enough TERT protein to
completely replicate their telomeres at each cell division and their proliferative capacity
decreases with the age of the organism [9]. With time, stem cell exhaustion impairs tissue
renewal. Because of this reason, telomere shortening has been recognized as one of the
hallmarks of human aging [10].
Telomere replication is also involved in the acquisition of the unlimited proliferative capacity
that characterizes tumor cells [7]. Telomerase expression and activity is induced in about 85%
of tumors, which allows tumor cells to completely elongate their telomeres at each cell division.
In the other about 15% of tumors, telomeres length is maintained by a telomerase-independent
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mechanism, know as Alternative Lengthening of the Telomeres (ALT) that elongates telomeres
through DNA recombination mechanisms [11].
The importance of telomere homeostasis is further enforced by the existence of a number of
rare hereditary diseases that are caused by the presence of shortened telomeres, collectively
named telomeropathies, short telomere syndromes or telomere biology disorders [12]. These
diseases are caused by mutations in genes coding for proteins involved in telomere lengthening
(telomerase complex and related proteins) or in the maintenance of telomere structure
(shelterin complex). These diseases are commonly characterized by the presence of very short
telomeres in the cells of the affected patients. The molecular pathology of these diseases, their
diagnosis and emerging therapies will be summarized in this chapter. It is necessary to enforce
the importance of telomere homeostaxis for healthy life since excessively long telomeres are
also causative of disease. Recent reports have associated the presence of long telomeres to
increased frequency of cancers such as melanoma or glioma [13]. Mutations in the promoter
region of the TERT gene that increase gene expression are frequently found in these and other
tumors [14, 15]. In addition, mutations in the coding region of genes coding for protein of the
shelterin complex have been found in human tumors [16, 17].
2. Main body
2.1. Telomere structure
Telomeres have a very specialized chromatin structure that is required to protect chromosome
ends from degradation and to avoid telomere-telomere fusions [2]. The general structure will
be briefly summarized in this section of the chapter and is schematically shown in the upper
panel of Figure 1 where the genes mutated in telomere biology disorders are indicated by
asterisks. Telomere structure has been the subject of several recent excellent reviews [2, 12, 18,
19]. The nucleotide sequence of telomeres is composed for multiple repetitions of the TTAGGG
hexanucleotide in humans and several other animals. The length of these regions is variable
in different organisms. In humans, telomeres have and average size of 8-14 kb in peripheral
blood cells in new born children [20]. The size decreases with age so that the average size in a
90-years old person is of 3-7 kb [12]. In contrast, most mice strains used in research have an
average telomere length of 50-100 kb which has made more difficult the development of mouse
models of telomere biology disorders [21, 22].
Telomere ends are not formed by blunt-ended double-stranded DNA, as might be expected.
Instead, the 3’ strand is about 75-300 bases longer than the 5’ end strand forming an over‐
hanging single-stranded DNA fragment (Fig 1, upper panel) [1]. The overhanging strand
contains the TTAGGG sequence and is, therefore, known as the G-rich strand. The comple‐
mentary strand contains the complementary CCCTAA repeats and is named the C-rich strand.
The overhanging strand is not unstructured. Instead, it turns over the telomere DNA and
intercalates in the neighbouring double-stranded DNA forming a loop, named the T-loop, as
schematically shown in the upper panel of Figure 1 [23]. Looping results in the formation of a
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triple stranded DNA region known as D-loop that is required for the stability of the terminal
telomeric DNA region [24].
Telomeres are further stabilized by the presence of a specific protein complex, the shelterin
complex. It is composed by six different proteins: TRF1, TRF2, RAP1, TIN2, TPP1 and POT1
(upper panel of Figure 1] [2]. TRF1 (telomeric repeat binding factor 1, encoded by the TERF1
gene) binds to telomeric double-stranded DNA as a dimmer [25]. TRF2 (telomeric repeat
binding factor 2, encoded by the TERF2 gene) also binds double-stranded DNA as a dimmer
and associates with TRF1 [26]. The TIN2 protein (TRF1-interacting protein 2] interacts with
TRF1 and TRF2 [27] and recruits the POT1(Protection of telomeres protein 1]/TPP1(POT1-
interacting protein 1] heterodimer [28]. POT1 binds with high affinity to the G-rich strand
overhang [29]. RAP1 (repressor-activator protein 1] incorporates to the shelterin complex via
TRF2 interaction [28]. In addition, telomeres and subtelomeric regions are enriched in heter‐
ochromatin components including the association of HP1 proteins and histone 3 Lysine 9 and
histone 4 lysine 20 trimethylation which further contributes to their stability [30].
Figure 1. Telomere structure and elongation mechanism.
The shelterin complex is required for telomere maintenance and function and prevents the
recognition of telomeres as damaged DNA. TRF2 inhibits the ATM kinase that induces the
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canonical non-homologous-end-joining DNA repair pathway that would result in telomere-
telomere fusions [31]. In addition, POT1 inhibits signalling by the ATR kinase in response to
DNA damage by double-strand and single-strand breaks and alkylating agents [32]. POT1 also
inhibits sister-telomere associations [33].
Telomere structure is schematically shown in upper panel A of the figure. Telomeric DNA is
formed by repetitions of the TTAGGG hexanucleotide and is represented as two lines in the
figure. The upper line represents the leading, G-rich strand. The 3’ end of this strand is single-
stranded and forms a loop (T-loop) to hybridize to a region of the upstream double-stranded
DNA forming a smaller loop (D-loop). The lower line represents the lagging DNA strand.
Proteins of the shelterin complex, which binds to telomeric DNA, are represented as boxes.
Asterisks indicate the proteins whose encoding gene have been found mutated in patients with
telomere biology disorders. Panel B represent the components involved in telomere elonga‐
tion. DNA is represented as two lines and proteins as boxes, as indicated on panel A. The DNA
leading strand is the upper one and the DNA being synthesized is represented as a broken
line. The components of the telomerase complex that catalyzes telomere elongation are
represented on the right of the panel. Telomerase complex is composed by the TERT, DKC,
NOP10, NHP2 and GAR1 proteins and the RNA molecule TR. The protein TCAB1 is required
for telomerase recruitment to telomeres. PARN is required for TR RNA processing. The
RETEL1 helicase and the CTC1/SIN1/TEN1 complex facilitate telomere elongation by disrupt‐
ing DNA secondary structures. Asterisks indicate the proteins whose encoding genes have
been found mutated in patients with telomere biology disorders.
2.2. Telomere elongation
In this section a brief summary of the telomere elongation process and its regulation will be
presented because many of the proteins involved are related to telomere biology disorders. A
schematic representation of the process is shown at the lower panel of Figure 1. Genes mutated
in telomere biology disorders, as described in next sections, are indicated by asterisks.
Telomere replication has been reviewed recently by several authors [18, 19, 34-36]. Cellular
DNA polymerases cannot complete the replication of DNA double-strand ends which is know
as the end-replication problem [37], as mentioned in the Introduction section. In mammals,
telomere DNA 3’ ends are elongated by the telomerase complex through reverse transcription.
The catalytic activity of the complex resides in the TERT (telomerase reverse transcriptase)
protein [6] while the 454 nucleotides long TR (telomerase RNA, encoded by the TERC gene)
is used as template [38] (Figure 1, lower panel) [36]. This is because TR has an internal region
complementary to the TTAGGG repeats that allows hybridization to the 3’ end of the telomere
DNA [36]. The TR RNA has similarity to other small nucleolar RNAs and contains a H/ACA
motif [39]. It is transcribed by RNA polymerase II and contains a Cap structure and its 5’end
and a 3’ oligo-Adenosine tail [40]. It has been recently shown that the 3’ end of TR has to be
processed through exonuclease cleavage and that the Poly(A)-specific ribonuclease (PARN) is
required for this maturation process [41].
Additional proteins form part of the telomerase complex and are required for its assembly and
stability. Among them, dyskerin (encoded by the DKC1 gene) binds to TR through its inter‐
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action with the dyskerin PUA RNA binding domain [42]. Dyskerin binding is required for TR
stability and for its recruitment to the telomerase complex. The proteins NHP2 and NOP10
associate to dyskerin and are also required for telomerase assembly [43].
Telomerase activity is  dependent on TERT gene expression that is  tissue-dependent and
developmentally  regulated,  as  mentioned  in  the  Introduction  section.  In  addition,  it  is
dependent on protein-protein interactions that regulate telomerase-complex assembly and
its  recruitment  to  telomeres.  One  of  the  proteins  involved  is  TCAB1  (encoded  by  the
WRAP53  gene)  that  is  an  essential  component  of  the  subnuclear  Cajal  body structures.
TACB1associates  to  TR,  contributing  to  telomerase  assembly  in  these  structures  [44].
Depletion of TCAB1 results in a relocation of the telomerase complex to the nucleolus and
reduced  recruitment  to  telomeres  [44].  The  shelterin-complex  component  TPP1  is  also
required for the recruitment of telomerase to telomeres.  The TEL patch of TPP1, rich in
Glutamate  and  Leucine  residues,  interacts  with  the  TEN  domain  of  TERT  to  mediate
telomerase recruitment [45]. This interaction also promotes the telomerase ability to catalyze
repeated cycles of DNA synthesis at the telomeres [46].
After elongation of the G-rich overhanging strand by the telomerase complex the C-rich strand
is synthesized by the activity of the primase/DNA polymerase complex [35]. Proteins with
helicase activity are required to facilitate telomere elongation through disruption of DNA
structures that impair telomerase and DNA polymerase activity. The G-rich nature of the
overhanging strand favours the formation of secondary structures such as G-quartets [47]. In
addition, the D-loop structure of telomeres can also impair DNA synthesis. One of the proteins
involved in solving DNA structures at the telomeres is RETEL1 (regulator of telomere length
1], a DNA helicase with D-loop-disrupting activity that has been proposed to facilitate T loop
unwinding and to counteract the formation of G-quartets [48, 49]. In addition, RETEL1 has
additional functions at other DNA loci [50]. The CST complex, formed by the CTC1, STN1 and
TEN1 proteins promotes the initiation of the lagging C-rich strand synthesis [51]. CTC1 binds
to the single-stranded G-rich DNA strand and recruits the initiator Polα primase complex to
accomplish C-rich strand synthesis [52].
Once DNA synthesis is completed at telomeres, DNA is further processed to generate the G-
strand overhangs [35]. This is a highly regulated process so that G-strands overhangs are
between 30 and 400 nucleotides long and the C-rich strand ends at the 3’-CCAATC-5’ sequence
in most telomeres [53]. Processing requires the activity of several factors: the Apollo/SNMB1
nuclease, Exonuclease I, the CST complex and two shelterin proteins, POT1 and TRF2 [54].
It is important to enforce that although telomere structure and replication have been presented
separately for simplicity they are highly interconnected processes. For example, proteins of
the shelterin complex play essential roles in telomere elongation through recruitment of the
telomerase complex and proteins involved in the regulation of telomere length.
2.3. Telomere biology disorders
Several diseases related to telomere biology will be described in this section. The clinical
manifestations of each disease will be described together with their molecular bases. These
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diseases are multisystem genetic disorders that share many of the affected genes (see [12, 13,
18, 19, 55-58] for recent reviews). They also have in common the presence of very short
telomeres in the affected patients. However, time of onset, phenotype and clinical severity of
these diseases are very heterogeneous. Some of the disorders manifest in young children as it
is the case of Dyskeratosis congenita, Hoyeraal-Hreidarsson syndrome, Revesz syndrome and
Coats plus syndrome that are rare diseases presented with very low frequency in the popula‐
tion. Other diseases that manifest at older ages, generally in adults, are less severe and more
frequent in the population. Among these are Aplastic anemia, Lung disease and Non-alcoholic,
non-infectious liver disease. A summary of these diseases, their clinical manifestations, time
of presentation and the genes that have been found mutated is shown in Table 1.
Disease Symptoms Presentation time Mutated genes
(inheritance)*
Dyskeratosis congenita Nail dysplasia Childhood DKC1 (XL)
Abnormal skin pigmentation TERT (AD,AR)
Oral leukoplakia TERC (AD)
Bone marrow failure TINF2 (AD)
Pulmonary fibrosis WRAP53 (AR)
Liver abnormalities NOP10 (AR)
Avascular necrosis of the hips NHP2 (AR)
Stenosis of the exophagus, lacrimal ducts
and/or uretra
CTC1 (AR)
Increased cancer risk RTEL1 (AD,AR)
Osteopenia, risk of bone fractures PARN (AR)
Psychiatric disorders
Hoyeraal-Hreidarsson
syndrome
Intrauterine growth retardation Early childhood DKC1 (XL)
Microcephaly TINF2 (AD)
Cerebellar hypoplasia TERT (AR)
Thrombocytopenia RTEL1 (AR)
Immunodeficiency TPP1 (AR)
Nonspecific enteropathies PARN (AR)
Bone marrow failure
Revesz syndrome Bilateral exudative retinopathy Early childhood TINF2 (AD)
Bone marrow failure
Intrauterine growth retardation
Intracraneal calcifications
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Disease Symptoms Presentation time Mutated genes
(inheritance)*
Developmental delay
Fine, sparse hair
Nail dystrophy
Coats plus syndrome Bilateral exudative retinopathy Early childhood CTC1 (AR)
Retinal telangiectasias
Intrauterine growth retardation
Bone abnormalities with poor healing
Gastrointestinal vascular ectasias
Aplastic anemia Bone marrow failure Middle age TERC (AD)
TERT (AD)
Idiopathic pulmonary
fibrosis
Pulmonary fibrosis Middle age TERC (AD)
Emphysema TERT (AD)
Interstitial pneumonitis PARN (AD)
Honeycombing in high resolution
computarized tomography
RTEL1 (AD)
Nonalcoholic, noninfectious
liver disease
Hepatic fibrosis Middle age TERC (AD)
Noncirrhotic portal hypertension TERT (AD)
Hepatopulmonary syndrome
*XL: X-linked; AD: autosomal dominant; AR: Autosomal recesive
Table 1. Clinical characteristics of telomere biology disorders.
2.3.1. Dyskeratosis congenita
Dyskeratosis congenita (DC) was the first telomere biology disease described in early 1900s
[59]. It is an inherited disorder that is usually diagnosed in early childhood. The most charac‐
teristic clinical feature is a triad of mucocutaneous features: leukoplakia, reticulated skin
pigmentation and nail dystrophy, as shown in Table 1. Lacy reticular pigmentation use to be
observed at neck and upper chest. However, DC symptoms have variable expressivity and/or
incomplete penetrance and this triad is not always present. Some patients worsen with age
and the triad might not be evident in the firsts examinations. The median age of appearance
of the triad is approximately 8 years [59]. The variability in the nail phenotype can go from
ridging to complete nail loss and can involve both the finger and toenails. The skin may be
hyper or hypo pigmented. Leukoplakia may affect other mucosa surfaces. However, additional
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reports expanded the phenotype and it is now recognized as a multisystem disease. One of
the most common haematological manifestations is bone marrow failure that is the most
significant cause of mortality in DC patients, up to 60-70% [60]. Patients present hypocellular
bone marrow and severe cytopenias.
DC patients frequently show other skin manifestations, some of them are atrophy of the dorsal
surface of hands and feet,hyperhydrosis and hyperkeratosis of palms and soles. Other mucosal
surfaces can also be affected leading to stenosis of the oesophagus, urethra or lacrimal duct.
Oesophageal strictures and non-specific enteropathies are common. Dental abnormalities can
be also observed including extensive caries in 13-17% of the patients [61]. Early greying and
loss of hair also occur. Skeletal abnormalities are also observed in up to 5% of the patients [62]
including osteoporosis and avascular necrosis. Osteoporosis resembles that seen in natural
aging and can led to fractures [63].
Respiratory abnormalities are also a significant cause of morbidity and mortality and cause
the death of 10-15% of DC patients [64]. The main clinical manifestation is pulmonary fibrosis
that usually is posterior to the mucocutaneous or bone marrow features. Hepatic disease can
be also observed including cirrhosis, fibrosis, portal hypertension and portal vein thrombosis
and several cases of non-alcoholic, non-infectious liver diseases have been reported [65].
Neuropsychiatric disorders were recently described in 55% of children and 75% of adult DC
patients [66]. These disorders include mood, anxiety, psychotic and adjustment disorders,
attention deficit/hyperactivity, intellectual disability, learning disabilities and pervasive
developmental disorders.
DC patients also present increased risk of cancer development. Co-occurrence of Myelodys‐
plastic syndrome (MDS), Acute myelogenous leukemia (AML) and head and neck squamous
cell cancer has been described. A literature review reported a 11-fold increased risk of cancer
in DC patients including AML, MDS, tongue cancer, cervical squamous cell carcinoma and
non-Hodgkin’s lymphoma, with a risk of 40% of developing any cancer by the age of 50 [67].
This diversity in clinical manifestations makes the diagnosis of DC challenging. When the
mucocutaneous triad is observed the diagnosis is relatively clear but this is not always the case.
Vulliamy et al proposed in 2006 clinical criteria for the diagnosis of DC [68]. These criteria
require the presence of the three components of the mucocutaneous triad or one feature of the
triad, bone marrow failure and two other clinical manifestations usually found in DC patients,
as described above. However, the diagnosis of some patients can still be difficult because the
triad might evolve late in time and other clinical manifestations might not be associated to DC
because of their diversity.
2.3.1.1. Dyskeratosis congenita as a telomere biology disease, implications in diagnosis
Dyskeratosis congenita may have X-linked inheritance which allowed the identification of one
X-chromosome gene that presented missense mutations in several unrelated DC patient. The
encoded protein was named dyskerin and the gene DKC1 [60, 69]. Dyskerin was characterized
as a highly conserved protein with possible nucleolar functions [60]. Soon afterwards,
fibroblasts derived from DC patients were shown to have very short telomeres [70]. These cells
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also presented reduced telomerase activity and decreased levels of TERC expression. The
correlation between Dyskeratosis and telomere length was strengthened when a large family
was found carrying an autosomal dominant mutation in the TERC gene [71].
The recognition of DC as a telomere biology disease helped to understand the biology of this
disease. As mentioned in the Introduction, critically short telomeres are recognized as
damaged DNA by DNA-damage response pathways that involve the ATM and ATR protein
kinases and the p53 protein. Activation of these pathways induces apoptotic cell death and
cellular senescence. Telomere shortening is associated to DNA replication, which is specially
relevant in cells that have impaired systems of telomere elongation and protection, as is the
case of DC patients cells. Therefore, highly proliferative cells are expected to be the firstly
affected by telomere shortening. Some of these highly proliferative cells are the stem cells of
tissues with high capacity of renewal such epithelia, bone marrow cells and lymphocytes.
These cells types are characterized by the expression of high telomerase activity in healthy
individuals. Depletion of these stem cell populations can explain the main clinical manifesta‐
tions of DC patients. Among them are the deficit observed in epithelial tissues such as different
mucosa and skin that could be due to insufficient cell renewal because of exhaustion of stem
cell populations. Impaired proliferation of bone marrow stem cells also could explain the
existence of hypocellular bone marrow and severe cytopenia. Pulmonary alveolar stem cell
failure has also been recently described in patients with telomere dysfunction [72]. The
reduction in the number and proliferative capacity of stem cells can also explain the premature
aging of DC patients as manifested by hair loss and early greying. These data would recognize
DC as a stem cell disease.
A second clinical characteristic associated to progressive telomere shortening is the existence
of genetic anticipation. It is defined by the occurrence of increasing disease severity and early
onset with successive generations, as observed in multigenerational families with autosomal
dominant DC [73-75]. Genetic anticipation is due, in these diseases, to non-complete telomere
replication in germinal cells due to impaired telomerase activity. Successive generations inherit
progressively short telomeres and, therefore, critically short telomeres appear at an early age
in highly proliferative tissues of the affected patients.
The identification of telemere shortening also provides one important diagnostic criteria. DC
patients are characterized by the presence of very short telomeres in peripheral blood cells.
Usually bellow the 1% of the telomere size of control populations of the same age as the patient.
Measuring telomere length provides one differential diagnostic criteria for telomere biology
diseases. The length of telomeres can be determined by different methods in patient samples
[76] and compared with controls of the same age. Variation of telomere length with ethnicity
has also been described [77]. One of the methods estimates telomere length by Southern blot.
Purified DNA is digested with a restriction enzyme that has recognition sites close to the
telomeres (sub-telomeric region) but not at the telomere. Digestion products are separated in
agarose gels and blotted to membranes that are hybridized to telomere-specific probes. The
distribution of telomeres size and average length can be determined by comparison to the
migration of DNA molecular weight markers. The use of this technique requires relatively
high amounts of pure DNA.
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Telomere length can also be determined by quantitative PCR methods from clinical samples.
Some of these methods use telomere-specific oligonucleotides to determine the amount of
telomeric DNA in comparison to non-telomeric DNA in each sample. This method has the
advantage that a large number of samples can be easily analyzed but it gives and average
length of all the cellular telomeres. However, variation in the length of individual chromo‐
somes can be also important in disease progression [78]. Telomeres rearrangements can also
have a large effect on the cell [79] and would not be detected by measuring average telomeric
DNA content. A PCR-based method that determines single telomere length (Single telomere
length assay, STELA) has also been developed [80]. Telomere length can also be determined
by flow fluorescence in situ hybridization (flow-FISH) using peripheral blood lymphocytes
[81]. This technique can be used in clinical settings and has been shown to be highly sensitive
and specific in identifying patients with DC from their unaffected relatives and healthy
controls [81, 82]. Flow-FISH is presently the only clinically certified test for DC.
2.3.1.2. Molecular genetics of Dyskeratosis congenita
DC is a rare inherited disease caused by mutations in genes coding for proteins involved in
telomere synthesis and protection. Mutations in ten genes have been identified to date in DC
patients [55]. Mutations in these genes explain about 60% of the cases of DC so that there are
many cases where the causative gene has not been identified. Until few years ago, molecular
diagnosis was made through PCR amplification and DNA sequencing of each exon of the
candidate genes, pre-analyzed by High Resolution Melting [83]. Discovery of new genes
involved in DC and related telomeropathies required positional cloning and were challenging
projects. The development of techniques of massive parallel DNA sequencing makes now
possible to sequence either all the genes of a patient (genome sequencing) or all the gene exons
(exome sequencing) [84]. Analyses of massive sequencing data greatly facilitates molecular
diagnosis as well as the discovery of genes whose causative relationship with the disease was
previously unknown. One example is the recent identification of mutations in the PARN gene,
coding for a Poly(A)-specific ribonuclease in DC patients [85]. The genetic mutations found in
DC patients will be reviewed in this section of the chapter and have been described in recent
reviews [18, 86]. A summary is also presented in Table 1. Detailed updated information on the
nucleotide variants found in DC-related genes can also be found at the Telomerase Database
(http://telomerase.asu.edu/diseases.html).
2.3.1.2.1 Dyskerin (DKC1]
Dyskerin is a 524 amino acids long protein that is highly conserved during evolution. It is an
essential nucleolar protein that is expressed in all tissues [42]. Dyskerin participates in two
very relevant cellular activities, telomere maintenance and RNA pseudouridylation. The first
activity has been described in the Telomere elongation section of this chapter (section 2.2]. For
the second activity dyskerin binds to small nucleolar RNAs containing the H/ACA box to form
small nucleolar RNP (snoRNP) complexes. The proteins NHP2, NOP10 and GAR1, involved
in telomerase assembly are also part of these complexes [42]. Small nucleolar RNAs guide
snoRNPs to specific uridine residues that are converted to pseudouridines by dyskerin.
Pseudouridylation takes place in many cellular RNAs including ribosomal RNAs but also
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small nuclear and nucleolar RNAs and mRNAs, as recently described [87]. This modification
is important for folding and processing of these RNAs [88]. One subset of snoRNPs (Cajal body
RNPs, scaRNPs) is directed to Cajal bodies by the TCAB1 protein [89]. The telomerase RNA,
TR, assembles as a typical scaRNP, which is important for TR stability and telomerase
recruitment [39, 70] as previously indicated (section 2.1]. Because of this pseudouridylation
activity of rRNAs, dyskerin is important for ribosome biogenesis and function, and dyskerin
mutations could impair protein synthesis. However, human cells obtained from X-linked DC
patients showed intact or only slightly affected ribosome biogenesis and function and very
reduced TR levels [90, 91]. These data support the hypothesis that impaired TR stability and
telomerase activity are the main cause of DC. However, Bellodi et al. have reported that
impaired protein synthesis could contribute to the cancer predisposition of DC patients [92].
Sequence analyses in the Pfam databank identified three functional domains in dyskerin:
the  dyskerin-like  domain  (amino  acids  48-106]  with  a  yet  unknown function;  the  TruB
pseudouridine  synthase  catalytic  domain  (aa  110-126],  and  the  PUA  RNA  binding  do‐
main (aa 297-370]. To date, over 50 different DKC1 mutations have been found in associa‐
tion with DC. Many of them were inherited but there were some that were generated de
novo in the patients. Not all these mutations show the same severe phenotype and 13 of
them cause the Hoyeraal-Hreidarsson syndrome, a more severe manifestation that will be
described in the section 2.3.2 of this chapter. Two of the DKC1 mutations are only found
in this  syndrome.  Most  DKC1 mutations  cluster  in  two regions  of  the  gene:  the  region
coding amino acids 2-72, at the N-terminus of the protein, and the region coding amino
acids 314-420, at the PUA domain [68, 86]. These two domains are contiguous in the three-
dimensional structure of the protein and might form a binding site for other proteins [93].
Some disease-causing mutations have been show to alter dyskerin-TR binding because they
affect binding of the RNP assembly factor SHQ1 [94]. N-terminal DKC1 mutations overlap
a SUMOylation motif  and Brault  et  al  have shown that impaired SUMOylation leads to
reduced dyskerin,  and TR, levels [95].  A mutation in the promoter region of DKC1 that
affected dyskerin expression was also identified in a DC patient [96] suggesting that protein
levels  could  have  an  important  role  in  DC  pathogenesis.  DKC1  is  encoded  in  the  X-
chromosome and dyskerin mutations have X-linked transmission with affected males and
carrier mothers. In most of the cases carriers do not show any clinical manifestation but
carriers of some mutations can manifest late onset diseases such as pulmonary fibrosis that
will be described in section 2.3.6.
2.3.1.2.2 Telomerase Reverse Transcriptase (TERT)
The catalytic protein component of the telomerase complex is one 1132 amino acid long
protein that contains three major functional domains conserved trough evolution [97]. The
telomerase  essential  N-terminal  (TEN)  domain  is  highly  conserved  among  vertebrate
proteins  and  has  been  implicated  in  telomere  DNA  binding  upstream  of  the  primer-
template interaction [98]. The TEN domain contains a DAT motif involved in telomerase
recruitment  to  the  telomeres  through  interaction  with  the  TEL  patch  of  TPP1  shelterin
component.  The TERT RNA-binding domain (TRBD) is located next to the TEN domain
and precedes the reverse transcriptase domain, which contains the active site for reverse
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transcription.  In  addition,  the  reverse  transcriptase  motif  also  participates  in  TR  RNA
binding  ensuring  the  maintenance  of  a  stable  telomerase  complex  [99].  Finally,  TERT
contains a less-conserved C-terminal extension region.
Comparative analysis of the TERT gene in healthy individuals and telomere biology disorder
patients has shown a high degree of nucleotide variation. More than 200 distinct missense
nucleotide variants are described in the TERT gene at the Exome Aggregation Consortium
(ExAC) database (http://exac.broadinstitute.org/). This database compiles all the nucleotides
variants found in the different Exome sequencing projects and presently accumulates infor‐
mation from about 60.700 individuals [121.400 alleles for each gene). Data from both healthy
individuals and patients from different diseases are incorporated to this database. Over 75
TERT mutations, most of them novel, have been reported in telomere biology disorders
diseases [100], including missense, stop gain, frameshift and splice site mutations. However,
the existence of a given mutation in a patient does not imply that it is causative of the disease.
It might be a mutation that does not affect protein functionality. The existence of a familiar
history showing a strong correlation between the presence of the mutation and disease
manifestation would support the causative role of this mutation. However, if it is a novel
mutation, or the family history is short, experimental assay of the activity of the mutated
protein is required to ascertain the possible causal role. For this purpose, mutated TERT
proteins are expressed in cells that have very low telomerase activity, if any. The activity of
the mutated protein can be consequently tested on this background using the telomere repeat
amplification protocol (TRAP) or primer extension assays (see Collopy et al [101] for a recent
example).
TERT mutations associated with DC and other telomere biology disorders are found all over
the protein although their frequency is higher at the reverse transcriptase domain. Most
reported patients with TERT mutations are monoallelic heterozygous. The telomerase activity
found in cells from these patients is an average of homozygous wild type and mutant cells and
might indicate that haploinsufficiency is the cause of the clinical phenotype [74, 102, 103].
2.3.1.2.3 Telomerase RNA, TR (TERC)
The RNA component of the telomerase complex is 454 nucleotides in length and is encoded
by the TERC gene. This RNA provides the template sequence for reverse transcription and is
involved in assemblage of the RNP complex [104]. The interaction between TR and TERT
regulates the catalytic activity, processivity and telomere-binding activity of the telomerase
complex [105]. TR presents domains conserved through evolution that are involved in RNA
stabilization, accumulation, subcellular localization and telomerase assembly. They are the
template/pseudoknot domain and the CR4/5 motif [106]. These two domains are sufficient to
restore telomerase activity when combined with TERT [107, 108]. An additional H/ACA
domain at the 3’ end of TR allows binding of the proteins required for telomerase biogenesis
dyskerin, NOP10, NHP2 and GAR1 [43].
Mutations in TERC are less frequent than in TERT in DC patients and approximately 60
different mutations have been reported [100]. Nucleotide variants are also less frequent in the
general population and only 62 are reported in ExAC exomes database. Among the mutations
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found in DC patients some deleted large segments that affect functional domains while others
are nucleotide substitutions. Mutations are particularly frequent at the pseudoknot domains
and present an autosomal dominant inheritance (http://telomerase.asu.edu/diseases.html). As
indicated for TERT, the functional significance of TERC mutations, specially nucleotide
substitutions, has to be determined experimentally. A relevant example determined functional
properties such as TR stability, TERT interaction, telomerase activity and processivity of 13 TR
mutations [109].
2.3.1.2.4 TERF1- interacting nuclear factor 2 (TINF2]
The gene TINF2 codes for the protein TIN2, component of the shelterin complex that protect
the telomere and regulates telomerase recruitment and activity. TIN2 links the double-
stranded DNA binding proteins TRF1and TRF2 to the single-stranded DNA binding proteins
TPP-1 and POT1 within the shelterin complex. TIN2 also interacts with heterochromatin
protein 1 gamma (HP1γ) [110] through the canonical PTVML binding site [111] which is crucial
for sister telomere cohesion.
Over 20 mutations in TINF2 have been described in DC patients. Many of them are novel
mutations and results in early-onset disease.  Familiar mutations are usually inherited in
autosomal-dominant manner [111, 112]. All TINF2 mutations reported to date cluster in a
segment coding for 34 amino acids centrally located in the gene. The function of this short
protein fragment is  not clear at  the present time.  One of  the functions affected in some
TINF2 mutants is HP1γ binding [110] which could be explained because the PTVML binding
site is located within the mutation cluster [111]. Impaired HP1γ binding resulted in reduced
sister telomere cohesion. On the contrary, the interaction of TIN2 with TERF1 is not affected
in  most  of  the  mutated  proteins  [112,  113].  Impairment  of  telomerase  recruitment  to
telomeres in a  TIN2 mutant  has been reported [114].  However,  the telomere shortening
observed in  a  mouse model  of  TINF2 mutation was  recently  reported to  be  telomerase
independent [115].
2.3.1.2.5 TCAB1: Driving telomerase to Cajal bodies (WRAP53]
The protein TCAB1 (encoded by the WRAP53 gene) [116] binds to the telomerase RNA, TR,
through the 4 nucleotides CAB box, present on small Cajal body-associated RNAs. Telomerase
recruitment to Cajal Bodies is required for consequent assembly on the telomeres [44, 117].
Compound heterozygous mutations in WRAP53 have been identified in DC patients [118].
Telomerase localization to Cajal Bodies was disrupted in this patients leading to TR accumu‐
lation in the nucleoli. Mutations map to a region that mediates interaction between TCAB1
and the TCP-1 Ring Complex (TRiC) that is required for TCAB1 folding.
2.3.1.2.6 Nucleolar protein 10 (NOP10, Nola3]
Nucleolar protein 10 (NOP10] is encoded by the Nola3 gene (nucleolar protein family A,
member 3]. This protein is a H/ACA snoRNA-binding protein that binds the TR RNA in
association with dyskerin and NHP2 [43]. One homozygous mutation has been found in a DC
patient that impaired TR binding and RNP assembly [119].
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2.3.1.2.7 NHP2 ribonucleoprotein (Nola 2]
Similarly to NOP10, the NHP2 protein, encoded by the NHP2 gene, also named Nola2, is a H/
ACA snoRNA-binding protein that associates to TR together with dyskerin [43]. One homo‐
zygous missense mutation in the NHP2 gene was described in a patient with severe DC while
compound heterozygous mutations were described in a second DC patient [120]. These
patients had decreased TR levels and short telomeres because of impaired telomerase assembly
and stability [119].
2.3.1.2.8 Conserved telomere maintenance component 1 (CTC1]
The protein CTC1 is one of the components of the CST complex (CTC1, STN1, TEN1] that
promotes re-start of the telomere lagging strand synthesis and fill-in C-rich strand synthesis
at the telomeres [51, 52]. CTC1 binds to single-stranded DNA at telomeres and associates with
the replication initiator polα primase complex.
Biallelic, compound heterozygous, CTC1 mutations were identified in a group of DC patients
[121, 122]. These mutations impaired the association of CSC1 with STN1, TEN1 and polα
primase, telomeric DNA binding and cellular localization [123]. To date, 10 CTC1 mutations
have been associated with DC patients [122].
2.3.1.2.9 Regulator of telomere elongation helicase 1 (RTEL1]
Regulator of telomere elongation helicase 1 is an essential DNA helicase that belongs to a small
family of these proteins involved in different genomic instability diseases [124]. At telomeres,
RTEL1 disrupts the D-loops resolving the T-loop structure [48]. RTEL1 is recruited to telomeres
by TRF2 in late S phase and is essential to prevent nuclease-dependent excision of telomere T-
circles [49]. RTEL1 also show G-quartet unwinding activity required for telomeric DNA
replication although this activity is independent of TRF2 [50]. In addition, RTEL1 has impor‐
tant non-telomeric functions in processes such as DNA-replication, DNA repair and homolo‐
gous recombination [125].
Whole-exome sequencing in DC patients and their families identified RTEL1 mutations that
could cause DC and related telomere biology disease such as the Hoyeraal–Hreidarsson
syndrome and Pulmonary Fibrosis, that will be described later (sections 2.3.2 and 2.3.6]
[126-128]. To date almost 30 RTEL1 variants have been reported in telomere biology diseases
patients. Most RTEL1 mutations are transmitted in autosomal recessive manner but autosomal
dominance has been also reported [126]. Some mutations map to functional protein domains
such as the helicase, harmonin homology or the C4C4 metal-binding motifs [129]. The RTEL1
R1264H mutation, that impairs RTEL1 interaction with TRF2, has been found in 1% of the
Ashkenazi Jewish population [130].
2.3.1.2.10 Poly(A)-specific 3’ exoribonuclease (PARN)
Poly(A)-specific 3’ exoribonuclease is a widely expressed protein with Poly(A) deadenylase
activity that participates in the regulation of global mRNA levels during development [131].
In addition, PARN also deadenylates small nucleolar RNAs [40]. A recent exome sequenc‐
ing study linked PARN mutations with pulmonary fibrosis and telomere shortening [128].
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A subsequent study, also based on exome sequencing, identified bialelic mutations in the
PARN gene in three families with individuals exhibiting severe DC [85]. Two of the families
were homozygous for one missense variant and one Splicing-altering variant, respectively.
The  third  affected  patient  was  a  compound  heterozygous.  These  patients  exhibited  re‐
duced TERC, DKC1, RTEL1 and TERF1 mRNA levels.  Cells from these patients showed
activated DNA-damage response associated to nuclear p53 regulation, cell-cycle arrest and
reduced cell  viability  upon UV treatment  [85].  These  results  supported  a  potential  link
between PARN, the p53-dependent pathway and telomere shortening [132]. A subsequent
study using cells derived from these patients has shown that PARN is required for the 3’-
maturation  of  the  telomerase  RNA  component  [41].  Specifically,  PARN  is  required  for
removal of the oligo(A) tails post-transcriptionally added to the TR 3’ end and that target
nuclear RNAs for degradation.
2.3.2. Hoyeraal-Hreidarsson syndrome
The Hoyeraal-Hreidarsson syndrome (HH) is frequently considered a severe variant of DC,
typically presented in infancy [133]. The first patients with this syndrome were described by
Hoyeraal et al [134] and Hreidarsson et al [135]. However, the eponym was first proposed in
1995 in a case report of a child with clinical features very similar to those described by Hoyer‐
aal and Hreidarsson [136]. About 50 cases of HH have been reported since the first descrip‐
tion [86]. HH is a multisystem genetic disorder and represents the extreme phenotype of the
telomere biology disorders. Peripheral blood cells from these patients present very short
telomeres, below the first percentile for their age. Clinical manifestations typically present early
in childhood. These patients present developmental problems such as cerebellar hypoplasia,
microcephaly, developmental delay and intrauterine growth retardation (IUGR). In addition,
typically present immunodeficiency and progressive bone marrow failure. In addition to these
specific symptoms, HH patients can also present clinical manifestations found in DC pa‐
tients. For example, the typical triad of mucocutaneous alterations shown in DC patients can
also be present at diagnosis or develop with time in HH patients. Other DC-associated symptoms
that are also present in some HH patients include immunodeficiency, prematurity, dysmorphol‐
ogy, gastrointestinal features and neurological symptoms. Among these symptoms, cerebel‐
lar hypoplasia is considered a requirement for the diagnosis of HH [75, 137]. Other neurological
complications  include  impaired  myelination,  seizures,  hypoplastic  corpus  callosum  and
intracranial calcifications (reviewed in Glousker et al. [86]). Immunodeficiency is observed in
a large proportion of HH patients with increased susceptibility to life-threatening infections.
Over half of the patients present with lymphopenia [86]. The T cell compartment is less frequently
affected although abnormalities of T cell proliferation have been observed [138]. There are also
some reports of severe combined immunodeficiency [139]. Therefore, any child presenting with
humoral deficiency or combined immunodeficiency and neurological features (microcepha‐
ly, cerebellar hypoplasia) should be considered a possible HH patient. Digestive tract anoma‐
lies are frequent in HH patients and include oesophageal strictures, severe enteropathy and
colitis [140]. Other clinical complications include skeletal malformations [141], urinary tract
abnormalities [136, 142], and ophthalmological signs [136, 142].
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2.3.2.1. Molecular genetics of Hoyeraal-Hreidarsson syndrome
As mentioned above, HH can be considered as severe form of DC and, in agreement with this
consideration, some of the genes mutated in DC are also found mutated in HH patients [86].
The specific mutations present in HH patients can be different to those found in DC so that
mutations that affect more importantly protein function are associated to HH. In other cases
the difference is found in allele composition so that some mutations are found in homozygosis
or compound heterozygosis in HH and in heterozygosis in DC. The mutations presently
associated to HH will be briefly described in the following paragraphs and the genes affected
are indicated in Table 1.
2.3.2.1.1 Dyskerin (DKC1]
DKC1 mutations cause DC and also HH so that 13 out of the over 50 different mutations
presently known cause DC and HH and two of them are only found in HH (T49M and S304N)
[68, 143]. No clear correlation has been found between the location of the mutation on dyskerin
functional domains and the severity of the disease. Indeed, some mutations are associated with
variable severity from mild DC to HH, like the A353V mutation [144]. The two HH-associated
mutations are located to the catalytic TruB domain suggesting that pseudouridylation activity
is important for telomerase function [143].
2.3.2.1.2 Telomerase Reverse Transcriptase (TERT)
Mutations in the TERT gene have been found in HH patients but not as frequently as in DC
patients. From the more than 50 TERT mutations related to telomere biology disorders only
five are implicated in HH. Four of them cause HH in homozygosis (T567M, R901W) [145,
146] or compound heterozygosis (P530L, A880T) [147]. Carriers of these mutations have short
telomeres without reported clinical manifestations. The A880T and R901W mutations fall into
the TERT catalytic reverse transcriptase domain and the T576M mutation in the RNA-binding
domain. These mutations greatly impair telomerase activity and processivity, respectively
[146]. Only one autosomal dominant TERT mutation has been associated with HH (F1127L)
but it was also found in the healthy mother with could indicate the presence of a second,
paternal, mutation or disease anticipation [148].
2.3.2.1.3 TERF1- interacting nuclear factor 2 (TINF2]
The shelterin component TIN2 is encoded by the gene TINF2 and has an important role by
interacting with the double-stranded DNA binding proteins TRF1/TRF2 and the single-
stranded DNA binding heterodimer TPP1/POT1, as mentioned above. Three of the over 20
DC-associated TINF2 mutations have been found in HH patients. These mutations were de
novo or inherited in an autosomal-dominant manner [100, 111].
2.3.2.1.4 Regulator of telomere elongation helicase 1 (RTEL1]
The RTEL1 protein is a DNA helicase required for telomere replication, as mentioned above.
Presently, 18 RTEL1 mutations have been described in 17 HH patients. Most RTEL1 mutations
were biallelic, with either homozygous or compound heterozygous recessive inheritance. The
mutations were located in domains involved in protein-protein interaction or ubiquitin
transfer [127, 142].
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2.3.2.1.5 TPP1 (ACD)
The protein TPP1 (TINT1, PTOP, PIP1] is encoded by the Adrenocortical Dysplasia Homolog
(ACD) gene and is a component of the shelterin complex, as previously described (Section 2.1].
Three functional domains have been identified in this protein. The N-terminal OB domain is
involved in the interaction of TPP1 with TERT that participates in the recruitment of the
telomerase complex to telomeres through the TEL patch and increases telomerase processivity
[45, 46]. The central domain is required for heterodimer formation with POT1 [28, 149]. The
C-terminal domain binds TIN2 to form the shelterin complex, as mentioned above [150]. Whole
exome sequencing discovered a mutation at the TEL patch of TPP1 together with a missense
mutation in this same gene in a compound heterozygous HH patient [151]. The TEL patch
mutation was a single amino acid deletion and resulted in a reduction of telomerase proces‐
sivity and recruitment to telomeres. This same mutation has been identified in a family with
aplastic anemia and other DC symptoms and was transmitted in a dominant inheritance
manner [152].
2.3.2.1.6 Poly(A)-specific 3’ exoribonuclease PARN
The Poly(A)-specific 3’ exoribonuclease is involved in processing of the telomerase RNA, TR,
as mentioned above. A recent work identified PARN mutations in three families with indi‐
viduals exhibiting severe DC [85]. Actually, some of these patients had a disease classified as
HH syndrome associating PARN mutations to this disease [132]. These patients presented
biallelic mutations in the PARN gene indicating a recessive manner of inheritance.
2.3.3. Revesz syndrome
The syndrome of Revesz (RS) is a telomere biology disorder that affects young children. This
disease was first reported by Revesz et al as a case of a 6-month-old children with bilateral
exudative retinopathy that developed a severe bone marrow failure [153]. This and subsequent
reports indicated the following symptoms, summarized in Table 1: intrauterine growth
retardation, intracranial calcifications, developmental delay, fine spare hair and nail dystro‐
phy. The clinical presentations have several symptoms in common with DC and the specific
diagnosis of RS requires identification of bilateral exudative retinopathy [154]. Besides
common manifestations, the relation of RS with DC and other telomere biology disorders was
confirmed because RS patients have very short telomeres and present mutations in the TINF2
gene, that encodes the TIN2 shelterin component [111].
2.3.4. Coats plus syndrome/CRMCC
The Coats plus syndrome (CPS) is also known as cerebroretinal microangiopathy with
calcifications and cysts (CRMCC). Coats plus patients have bilateral exudative retinopathy,
retinal telangiectasias, intrauterine growth retardation, intracranial calcifications, bone
abnormalities with poor healing, and gastrointestinal vascular ectasias (Table 1). Some patients
also present DC-related features such as dystrophic nails, sparse or greying hair and anemia.
Intracranial calcifications and bilateral exudative retinopathy are also present in RS patients
but Coats plus patients also present cerebellar and hematologic manifestations [12, 56].
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Autosomal recessive compound heterozygous mutations in CTC1 have been described in CPS
identifying this syndrome as a telomere biology disorder [155-157]. As mentioned above, the
protein Conserved telomere maintenance component 1 (CTC1] is required for telomere
elongation. Actually, mutations in CTC1 probably account for most of the CTS cases. In
addition, telomeres that are bellow the first percentile for age have been found in CTS patients
and telomeres from heterozygous carriers have a length bellow average [155].
2.3.5. Aplastic anemia
Aplastic anemia is one of the clinical manifestations of telomere biology disorders in adults
usually associated to mutations in TERT and TERC. Symptoms in these patients are milder
than in children and mucocutaneous features are infrequent [12, 56]. Aplastic anemia can have
very different causes and there are inherited and acquired forms of the disease. Acquired forms
can be related to environmental exposures and infectious, among other factors, and is immune-
mediated. Inherited aplastic anemia has been reported to occur in patients with Fanconi
anemia, Shwachman-Diamond syndrome and other inherited bone marrow failures, including
DC. It has been described that approximately 10% of patients with isolated aplastic anemia
have mutations in TERC and TERT genes [158]. These mutations usually present an autosomal
dominant manner of inheritance. Telomere length in these patients is usually bellow the 10%
percentile for age [159]. The existence of symptoms related to telomere biology disorders in
relatives of these patients, such as pulmonary fibrosis, mild cytopenias, leukemia and squa‐
mous cell cancer, can be of great help for their diagnosis [12].
2.3.6. Pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a lung disease characterized by progressive interstitial
fibrosis that has a poor prognosis (median survival time of 2-3 years) [160]. Diagnosis of
pulmonary fibrosis, also known as interstitial pneumonia, is made by the presence of honey‐
combing on high-resolution computarized tomography (HRCT). In addition to pulmonary
fibrosis, these patients can present a range of pulmonary pathologies, including bronchiolitis,
obliterans organizing pneumonia, chronic hypersensitive pneumonia and emphysema alone
or combined with pulmonary fibrosis (Table 1) [56]. Familial forms of pulmonary fibrosis have
been also described and might represent up to 20% of the cases [161]. The study of these familial
forms identified mutations in TERT and TERC in 8-15 % of the cases [162, 163], establishing
IPF as a telomere biology disorder. IPF is inherited in these families as an autosomal dominant
trail. This observation is supported by animal models since TERT null mice have decreased
number or alveolar epithelial cells [164]. TRF1 deletion in type II alveolar cells also causes
pulmonary fibrosis in mice [165].
Heterozygous mutations in genes coding for telomere-related proteins have been found in
15-20% of IPF families without a history of DC [162, 163, 166] and 1-3% of sporadic cases of
IPF [167]. In addition, 20% of patients with DC develop pulmonary fibrosis [57, 58]. In
agreement with these observations, IPF patients have significantly shorter telomeres than age-
matched controls. Actually, IPF is the most common manifestation of telomere biology
disorders since DC and AA have much lower prevalence [168]. IPF due to telomere disfunction
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presents in adulthood, into middle age [164]. The gene most frequently mutated in IPF patients
is TERT [8-15% of familial cases) but mutations have been also found in TERC (<1%), DKC1
(<1%)[169], TINF2 (<1%)[170], RTEL1 [5%)[128, 166] and PARN [4%) [128]. TERT mutations
have been also found in smokers with severe emphysema at a frequency of 1% [171]. Telomere
dysfunction due to these genetic mutations can originate irreversible alveolar stem cell failure
that would be at the origin of pulmonary fibrosis and emphysema [72, 162]. IPF patients that
carry mutations in telomere-related genes can also present extra-pulmonary manifestations
related to telomere biology disorders such as bone marrow failure including red blood cells,
single lineage cytopenias or aplastic anemia [164]. Actually, the complex syndrome of IPF and
bone marrow failure predicted the presence of TERT or TERC mutations in 10 families that
presented these diseases in consecutive generations [172].
Short telomere length is a common finding in IPF patients, even in those without mutations
in telomere-related genes [167]. These results could indicate that IPF may be more likely to
develop in those individuals that naturally present shorter telomeres in the general population.
These individuals might also have increased incidence of other telomere-related disorders
such as cryptogenic liver cirrhosis and diabetes [58].
2.3.7. Liver disease
The study of five families with liver disease in combination with hematologic and autoimmune
disorders identified mutations in TERT and TERC [65]. A subsequent study of patients with
idiopathic live cirrhosis also found an increased frequency of TERT and TERC mutations [3.7%
vs 0,85% in the control population) [173]. Affected patients presented reduced telomerase
activity and short telomere length in peripheral blood cells. They also have increased proba‐
bility to progress to end-stage liver disease. In addition, liver disease, including hepatic
fibrosis, noncirrhotic portal hypertension, and hepatopulmonary syndrome has been reported
in DC patients (Table 1) [62, 64].
2.4. Treatment of telomere biology disorders
Treatment of diseases with several organs potentially compromised has many practical
complications. Presently, there are no curative therapies for many of the clinical manifestations
of telomere biology disorders. The major causes of decease in these patients are bone marrow
failure and pulmonary fibrosis and in this section we will summarize the present treatment of
these pathologies. In the second part we will describe some of the experimental strategies that
are being used to generate new therapies for telomere biology disorders.
2.4.1. Present treatment of telomere biology diseases
Hematopoietic stem cells transplantation (HSCT) is the only treatment than can cure bone
marrow failure in these patients. Donor’s selection requires special attention in telomere
biology disorders since relatives might be silent carriers of the mutations, given the clinical
heterogeneity of these diseases. This circumstance has been reported in two cases and there
was a failure either to engraft or to mobilize stem cells from the graft [174]. Analysis of the
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outcome of 34 DC patients transplanted with bone marrow indicated higher rates of mortality
and morbidity due to respiratory complications and graft failure [175]. Best results were
obtained transplanting grafts from HLA-matched siblings but the 10-year probability of
survival was 30% in this study. Conditioning of transplanted DC patients may also contribute
to long-term development of pulmonary fibrosis and liver disease. Therefore, the use of
reduced intensity conditioning, avoiding radiotherapy, busulfan and high dose of cyclophos‐
phamide might benefit to these patients [176].
Androgen therapy has been also used for telomere biology disorder patients with bone marrow
failure. These patients seem to be responsive to male hormones [177]. The mechanism involved
seems to be that male hormones modulate TERT gene expression and increase telomerase
activity [178]. In a retrospective analysis of 16 DC patients treated with androgens, 11 achieved
clinically significant hematologic response [179]. Telomere elongation after androgen treat‐
ment has been reported in one case [180]. However, androgens can have side effects such as
masculinisation, liver function abnormalities, hyperlipidemia and splenic peliosis (when
androgens are used in conjunction with GCSF) and telomere biology disorders patients can be
specially sensitive to these effects [181]. The androgen-stimulating hormone Danazol has less
masculinising side effects and has been also used for treatment of DC patients [182].
Treatment of idiopathic pulmonary fibrosis is presently mainly supportive with pulmonary
rehabilitation therapy and the administration of supplemental oxygen. Recently, two phar‐
macological agents, pirfenidone [183] and nintedanib [184] were shown to reduce lung
function decline in IPF patients. Danazol administration has also been described to slow down
the progression of pulmonary fibrosis in DC patients [182]. However, lung transplantation is
the only curative strategy available. Lung transplantation was successfully used in a patient
after HSCT [185]. The study of a small series of IPF patients with TERC or TERT mutations
showed a favourable short term output with 7 of 8 patients alive after a median follow-up of
1,9 years. However, frequent haematological, renal and infectious complications were
observed [186].
Because of the lack of curative therapies, telomere biology disorder’s management are
presently based on supportive measures and close follow-up for medium and long term
complications [55]. Regular clinical review to monitor organ-specific disease progression, such
as haematological analysis and pulmonary function testing must be performed. Surveillance
for the appearance of dermatological and digestive tumours is important for early detection
and complete surgical resection. Preventive measures such as avoidance of potential carcino‐
gens (tobacco smoke, sun exposure) and adequate dental hygiene are also very important.
2.4.2. Experimental strategies for treatment of telomere biology disorders
Important efforts for the development of mice models of telomere biology disorders aimed to
the development of novel therapies have been made in the last years [187]. However, the
existence of very long telomeres in the mice strains used for experimentation [50-100 kb) has
made of this a difficult task. Mice strains with defective telomerase activity have been gener‐
ated [187, 188] but they have to be crossed for 4-5 generations before their telomeres are
sufficiently short to manifest telomere-associated defects [189]. The use of mice with short
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telomeres to generate telomerase-deficient strains provided a better experimental model [190].
Mouse models carrying mutations in DKC1 have been also generated [191]. More recently,
tissue-specific inactivation of genes related to telomere biology has been used to generate mice
models of these diseases. For example, mice models of bone marrow failure and pulmonary
fibrosis were generated by deleting the TRF1 gene in the hematopoietic compartment and type
II alveolar cells, respectively [165, 192]. However, these mouse models did not completely
reproduce the human disease and telomere size was not reduced [190, 191]. Mice lacking the
p53 C-terminal domain had short telomeres and suffer from aplastic anemia and pulmonary
fibrosis and could be a useful model for the study of telomere biology disorders [193].
Telomere biology disorders are caused by mutations in a single gene in most patients and could
be, therefore, amenable for gene therapy strategies. An important caveat is that telomere length
is narrowly controlled and excessively long telomeres increase the probability of developing
some cancers such as melanoma [13]. Mice over-expressing TERT also develop a large number
of tumors unless the tumor-suppressor protein p53 is also overexpressed [194]. Raval et al
recently showed that inducible reactivation of telomerase activity could reverse defective
hematopoiesis caused by telomere shortening in TERT-deleted mice [189] opening new
perspectives to gene therapy approaches. Transient expression of TERT also extends telomeres
in human cells [195]. Recent reports indicate that TERT plays roles beyond telomeres and
contributes to stem cells maintenance and cell reprogramming which might offer new
therapeutics targets for telomere biology disorders [196].
Telomere shortening results in the accumulation of DNA damage at telomeres and the
activation of the p53 pathway, as mention above. A DC mouse model in which mice carries a
DKC1 exon 15 deletion demonstrated that mutant cells had a growth retardation compared to
wild-type cells [191]. Mutant cells accumulated increased levels of DNA damage. In addition,
these cells are hypersensitive to oxygen and accumulate reactive oxygen species. Treatment of
these cells with the antioxidant N-acetyl cysteine increased cell growth, both in vitro and in
vivo. Competitive bone marrow repopulation studies showed that the DCK1 mutation is
associated with a functional stem cell defect consistent with accelerated senescence. This stem
cell defect was partially reverted by N-acetyl cystein treatment of the animals [197]. These
results suggest that antioxidant treatment may prevent or delay some DC manifestations.
A new therapeutic opportunity came from the observation that a dyskerin motif, correspond‐
ing to the TruB domain of the protein (GSE24.2], reactivated telomerase activity in DC-patients
and human telomerase-deficient cells [198]. This peptide activated human TERT promoter in
a c-myc expression-dependent manner. GSE24.2 rescued DC-fibroblasts from premature
senescence. The peptide also increased the telomerase RNA, TR, expression trough stabiliza‐
tion of the molecule [199]. DC-cells presented increased DNA damage at the telomeres and
increased levels of oxidative stress. Expression of GSE24.2 decreased both DNA damage and
oxidative stress of the cells that expressed a DKC1 mutant protein [200]. Subsequent studies
demonstrated that a shorter fragment of GSE24.2, named GSE4, maintained the same biological
activity and induced telomerase activity and cell proliferation of DKC-mutant cells. In
addition, DNA damage, oxidative stress and cell senescence were reduced upon expression
of GSE4 [201]. GSE24.2 could be delivered to cells using surface modified biodegradable
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polymeric nanoparticles, which might facilitate their administration to patients [202]. These
results open a new therapeutic opportunity for the treatment of telomere biology disorders
and GSE24.2 was recently approved by the EMA as an orphan drug for DC treatment (EU/
3/12/1070-EMA/OD/136/11].
2.5. Conclusion
Telomere biology disorders, also named telomeropathies, compose a group of diseases with
diverse clinical presentations, affecting several systems, but a common genetic etiology.
Telomere maintenance or protection is defective in the patients affected by these diseases and,
as a consequence, they present short telomeres. Critically short telomeres induce cell death or
senescence impairing cell proliferation. Cell renewal in adult tissues depends on the prolifer‐
ation of stem cells. In patients with defects in telomere biology, telomeres of stem cells are
shortened after each cell cycle and get exhausted much earlier than in healthy individuals
which impairs tissue renewal. This effect is specially important in highly proliferative tissues
such as bone marrow, lymphocytes and epithelial tissues, including lung alveolar epithelia,
that are the tissues mainly affected in patients with telomere biology disorders.
The severity of the disease seems to be dependent on the functional alterations that each
mutation causes in the biological activity of the corresponding protein. The genetic doses is
also very important since patients that are homozygous for the mutation or compound
heterozygous for more than one mutation usually present more severe symptoms of the
disease that manifest at an early age. These forms of the disease are inherited in a recessive or
X-linked manner. Heterozygous patients might be healthy carriers but they can also present
milder forms of the disease that present at an older age, generally in adults. These disease
manifestations are inherited in an autosomal dominant manner. There is also an association
between the severity of the disease and the tissues affected. High-turnover tissues are affected
in younger patients and as a more severe disease. For example, the main manifestation in
infancy is severe immunodeficiency affecting B cells, T cells and NK cells that have high
replication rates. Bone marrow defects manifests later in children and young adults as isolated
cytopenias and aplastic anemia. The gastrointestinal epithelium is also affected in children and
young adults. In contrast, telomere phenotypes predominantly manifest in slow-turnover
tissues such as lung and liver in adults [9]. There is also a strong correlation between the size
of the telomeres, as determined in peripheral blood cells, the severity of the disease and the
time of presentation so that patients younger and with more severe presentation have shorter
telomeres [12].
Genetic anticipation can also have a relevant influence in the presentation and evolution of
these diseases. As previously described, patients and healthy carriers of telomere biology
disease can transmit shortened telomeres to their descendants. If descendants are affected by
the disease, their stem cells will present critically short telomeres at an early age that the
previous generation, anticipating the time of onset and increasing the severity of the disease
[74]. For example, a large family has been described with several patients manifesting IPF,
bone marrow failure or a combined phenotype. There seemed to be a difference of several
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decades in the onset of the disease between generations with IPF manifesting in older indi‐
viduals (mean 51 years) and bone marrow failure in younger ones [14 years) [172].
The heterogeneous presentation of telomere biology diseases make difficult their diagnosis as
already mentioned in the description of DC (section 2.3.1]. In addition, some of the symptoms
also occur in patients with other diseases. For example, inherited bone marrow failure is also
observed in patients with Fanconi anemia, Shwachmann-Diammond syndrome and other
inherited BMFs. However, differentiating DC-associated BMF is important for patient
management since, for example, these patients often do not respond to immunosuppressive
therapy. One important criterion for diagnosis of telomere biology disorders is the presence
of short telomeres in comparison to the aged healthy population, usually lower than the 1%
percentile. However, some IPF patients present short telomeres even in the absence of
mutations in telomere biology related genes [167]. Therefore, an accurate diagnosis requires
establishing the molecular basis of the disease, identifying the causative mutation. Molecular
diagnosis can be done sequencing the exons contained in the genes presently known to be
mutated in telomere biology disorders. However, the high number of candidate genes and the
large number of exons present in some of them makes this approach time-consuming and
expensive. Alternatively, sequencing by exome sequencing techniques all exons of patients
and close relatives is becoming a more attractive, faster and cheaper method [84]. In addition,
exome sequencing allows the identification of mutations in genes that have not been previously
related to telomere biology (see [128] for a recent example).
These diseases can be considered and example of the importance of precision medicine for
diagnosis but also for patient managing and genetic counselling. The importance in diagnosis
is enforced by the elevated heterogeneity of the clinical presentations in several systems that
can create some uncertainty until a genetic analysis is performed. The importance for patient
management derives from the possible progressive alteration of different organs, as mentioned
above. This progression with time is very characteristic of telomerase biology disorders and
can only be predicted by a precise molecular diagnosis. Disease progression also determines
the therapeutic treatment. As mentioned above, the only curative alternatives are organ
transplantation, either hematopoietic stem cell transplantation (HSCT) or lung transplanta‐
tion. However, in telomere biology disorders both transplants have specific complications.
Reduced intensity conditioning is advised and patients frequently present graft failure. In the
case of HSCT respiratory complications have been described. In contrast, haematological, renal
and infectious complications were observed after lung transplantation. Both complications
could be expected for the multi-systemic nature of these diseases.
Precision medicine is also important for genetic counselling in telomere biology disorders [12].
Depending on the mutation, these diseases can have different manners of inheritance. The
phenotypic penetrance of each mutation can be different. Heterozygous clinically silent
carriers can be found whose long-term evolution is not yet understood. Patients treated for a
symptom can develop a different one later on. As mentioned above, supportive measures and
close follow-up of patients and carrier relatives is also very important. All these characteristics,
specific to these diseases, might be difficult to transmit to the patients and their relatives what
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makes even more important to provide appropriate genetic education and counselling to the
families.
As mentioned above, presently there are no really curative alternatives for these diseases. Lung
transplantation and HSCT are important therapeutic interventions but, unfortunately, with a
short time of survival. Some experimental therapies are promising but new curative therapies
are urgently needed and should be the focus of intensive research in the near future.
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